Flibanserin: initial evidence of efficacy on sexual dysfunction, in patients with major depressive disorder

The Journal of Sexual Medicine
Sidney Kennedy

Abstract

Flibanserin, a novel 5-HT(1A) agonist and 5-HT(2A) antagonist, has the potential to treat sexual dysfunction. Provide historical perspective on the rationale for development of flibanserin to treat sexual dysfunction, based on post hoc analyses of data. The Arizona Sexual Experiences (ASEX) scale and the Hamilton depression rating scale (HAMD) Genital Symptoms item. Sexual function outcomes are presented from four double-blind, randomized controlled studies involving a total of 369 men and 523 women diagnosed with Major Depressive Disorder. Each study had an active treatment arm to confirm assay sensitivity on the primary antidepressive endpoint. Two studies placebo, flibanserin (50mg bid), or fluoxetine (20mg qd) for 6 weeks and two involved placebo, flibanserin (50-100mg bid), or paroxetine (20-40mg qd) for 8 weeks. Individual study completion rates were 77-80%. At baseline, 38% of men and 67% of women reported sexual dysfunction. Assay sensitivity was not demonstrated in the fluoxetine trials and sexual function outcomes were inconsistent. Flibanserin and placebo were associated with low rates of treatment-emergent sexual dysfunction in women during the paroxetine studies. In one study, 70% of flibanserin-treated women with ...Continue Reading

References

Feb 18, 1999·JAMA : the Journal of the American Medical Association·E O LaumannR C Rosen
Aug 4, 1999·Depression and Anxiety·B K BoyarskyR M Hirschfeld
Jun 10, 2000·The Journal of Clinical Psychiatry·A J GelenbergP Delgado
Nov 14, 2000·Archives of General Psychiatry·C M Meston, P F Frohlich
Jan 18, 2002·Psychopharmacology·F Borsini, R Cesana
Feb 1, 1960·Journal of Neurology, Neurosurgery, and Psychiatry·M HAMILTON
Dec 1, 2004·The American Journal of Psychiatry·R Michael BagbyMargarita B Marshall
Apr 12, 2005·Psychopharmacology·Bríd Aine Nic DhonnchadhaMichel Bourin
Feb 12, 2008·BJU International·Edson D MoreiraUNKNOWN GSSAB Investigators' Group
May 21, 2009·The Journal of Sexual Medicine·James G Pfaus

❮ Previous
Next ❯

Citations

Nov 12, 2013·Neuroscience and Biobehavioral Reviews·Mirte BromPhilip Spinhoven
Nov 19, 2013·Pharmacology, Biochemistry, and Behavior·Lynda Uphouse
Jul 1, 2013·Sexual Medicine Reviews·Lesley MarsonUrsula Wesselmann
Dec 5, 2015·The Journal of Sexual Medicine·Alexander K ConverseDavid H Abbott
Sep 3, 2011·The Journal of Sexual Medicine·Louis F Fabre, Louis C Smith
Jan 14, 2012·The Journal of Sexual Medicine·Louis F FabreLeonard R Derogatis
Jan 18, 2012·The Journal of Sexual Medicine·Leonard R DerogatisUNKNOWN VIOLET Trial Investigators
Jan 14, 2012·The Journal of Sexual Medicine·John ThorpUNKNOWN DAISY trial investigators
Jan 29, 2011·The Journal of Sexual Medicine·Jennifer L Moll, Candace S Brown
Feb 18, 2011·The Journal of Sexual Medicine·Louis F FabreLeonard R Derogatis
Oct 30, 2010·The Journal of Sexual Medicine·Sue W Goldstein
Nov 22, 2011·Human Psychopharmacology·Angel MontejoSidney H Kennedy
Sep 29, 2015·Drugs·Emma D Deeks
Nov 26, 2015·Indian Journal of Psychiatry·T S Sathyanarayana Rao, Chittaranjan Andrade
May 7, 2016·Journal of Menopausal Medicine·Jae Hong SangSoo Ah Kim
Jun 24, 2017·Current Drug Targets·Nur Syazwani RoslanNik Hazlina Nik Hussain
Apr 3, 2020·Human Psychopharmacology·Hesham Y Elnazer, David S Baldwin
Dec 23, 2015·The Annals of Pharmacotherapy·Kristin RobinsonNicholas W Carris

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.